Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.10%. A quarter ago, it was expected that this medical products maker would post earnings of $2.38 per share when it actually produced earnings of $2.47, delivering a surprise of +3.78%.Over the last four quarters, the company has surp ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 Third Quarter DUBLIN, IRELAND - (February 4, 2026) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the thir ...

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $ ...

Key Takeaways STE is set to report Q3 on Feb. 4, with revenues seen at $1.48B and EPS at $2.53, up year over year. STERIS expects Healthcare momentum, with capital equipment orders robust and segment revenues up 8.1%. STE's AST and Life Sciences are seen growing about 8%, aided by organic growth and MedTech demand. STERIS plc (STE) is scheduled to release third-quarter fiscal 2026 results on Feb. 4, after market close.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.4 ...

DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued aft ...

Core Insights - The U.S. medical instrument and medtech sector is stabilizing as it enters 2026, with normalized procedure volumes post-pandemic and a focus on productivity and cost management [1][3] - Companies that can demonstrate operational improvements and earnings visibility are favored in the current investment environment, despite modest top-line growth [1][6] U.S. Macro Trends - Medtech equities are influenced by U.S. macroeconomic factors, particularly the Federal Reserve's interest rate policy, which is currently targeted between 3.5% and 3.75% [3] - Elevated labor and materials inflation rates have moderated, impacting margins more than demand, as companies align pricing and productivity with cost structures [4] Hospital Dynamics - U.S. hospitals are managing tight capital budgets while maintaining steady procedure volumes, benefiting companies with strong service and consumables revenue rather than those reliant on large equipment sales [5] - Staffing shortages are driving hospitals towards automation and efficiency, creating opportunities for device manufacturers offering productivity-enhancing solutions [5] Investment Opportunities in Undervalued Stocks - Undervalued medtech stocks may outperform through earnings recovery and multiple re-rating, as historical periods of uncertainty often compress valuations [6][7] - "Undervalued" stocks are defined as those trading below their historical valuation ranges, with potential for earnings growth through operational leverage and cost-reduction initiatives [7] Company-Specific Insights Fresenius Medical Care (FMS) - FMS is experiencing margin recovery due to cost savings and pricing improvements, with a current P/S F12M of 0.55x, below its 5-year median of 0.63x [10][11] - The company reported a rise in operating margin to 11.7% for Q3 2025, supported by cost savings and disciplined execution, with an expected earnings growth of 9% in 2026 [11][13] Integra LifeSciences (IART) - IART operates in neurosurgery and surgical instruments, currently trading at a P/S F12M of 0.59x, below its 5-year median of 2.14x [14][15] - The company anticipates supply normalization and margin expansion initiatives targeting $25-$30 million in savings, with expected earnings growth of 5.5% in 2026 [15][16] STERIS (STE) - STERIS provides sterilization services and is currently trading at a P/S F12M of 4.23x, slightly above its 5-year median of 3.97x [18][19] - The company reported high-single-digit organic revenue growth and expanded EBIT margin to 23.1%, with an expected earnings growth of 8.6% in 2026 [19][21]

Core Insights - STERIS plc (STE) is positioned for growth in the upcoming quarters, driven by its Healthcare segment and strong market adoption of its offerings, including infection prevention consumables and capital equipment [1] - The Applied Sterilization Technologies (AST) segment is experiencing robust service revenue growth, contributing positively to the company's overall performance [1] - The company has demonstrated sound financial health, enhancing its attractiveness as an investment [1] Financial Performance - STERIS has a market capitalization of $25.44 billion and an earnings yield of 3.9%, significantly higher than the industry's 0.5% yield [3] - In the past year, STERIS shares have increased by 26.7%, outperforming the industry growth of 5% and the S&P 500's rise of 21.1% [2] - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings per share (EPS) indicates a 10.9% increase to $10.23, with revenues expected to reach $5.93 billion, reflecting an 8.6% growth from fiscal 2025 [12] Healthcare Segment Performance - The Healthcare segment reported a revenue growth of 9% year over year in the second quarter of fiscal 2026, driven by a 10% increase in consumable revenues and a 4% increase in capital equipment revenues [4][7] - Service revenues in the Healthcare segment increased by 13% year over year, with order growth exceeding 3% year to date [4][7] - Margins improved due to increased volume, favorable pricing, and productivity gains, despite challenges from tariffs and inflation [4] AST Segment Performance - The AST segment achieved a 10% growth year over year in the second quarter of fiscal 2026, primarily due to a 13% increase in service revenues [5][7] - The segment benefits from a global network of over 50 contract sterilization and laboratory facilities, with a focus on ethylene oxide (EO) sterilization for single-use, sterile technologies [5] Financial Health - As of the end of the second quarter of fiscal 2026, STERIS had $319 million in cash, a long-term debt of $1.90 billion (down 0.3% sequentially), and no short-term debt [9][7] - The total debt-to-capital ratio was 21.3%, indicating a favorable solvency position [9] Market Challenges - The macroeconomic environment poses challenges, with rising healthcare costs impacting financial operations and increasing production costs due to raw material price fluctuations and tariffs [10] - STERIS faces intense competition from both large companies with extensive product portfolios and smaller firms, which may have greater resources for product development [11]

Founded in 1985, Mentor, Ohio-based STERIS plc (STE) develops, manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. The company’s market capitalization currently stands at $24.5 billion and is expected to unveil its Q3 2026 earnings report soon. Ahead of this event, analysts anticipate STERIS to generate earnings of $2.53 per share, representing an increase of 9.1% from $2.32 per share reported in the same qu ...

Steris (STE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnin ...

Core Insights - STERIS plc is a leading provider of infection prevention products and services, with a market capitalization of $25.7 billion, offering a diverse range of medical equipment and consumables [1][2] Company Overview - STERIS is categorized as a large-cap stock, emphasizing its significant size and influence in the medical devices industry, particularly in infection prevention [2] - The company’s diverse portfolio serves as a comprehensive solution for healthcare providers, enhancing revenue and customer retention [2] Stock Performance - STERIS shares have experienced a decline of 4.2% from their 52-week high of $268.60, reached on November 25 [3] - Over the past three months, the stock has gained 3.6%, underperforming the S&P 500 Index, which saw a 5% increase [3] - In the longer term, STERIS shares rose 6% over six months, lagging behind the S&P 500's 13.9% gains, but have outperformed the index with a 19.3% increase over the past 52 weeks compared to the S&P 500's 13% [4] Recent Financial Results - On November 5, STERIS reported Q2 results, with revenue of $1.5 billion, exceeding analyst expectations of $1.4 billion [5] - The adjusted EPS of $2.47 also surpassed analyst estimates by 5.1% [5] - In contrast, Stryker Corporation, a competitor, has seen its stock decline by 8.4% over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a bullish outlook on STERIS, with a consensus "Moderate Buy" rating from nine analysts [6] - The mean price target for STERIS is $288.86, indicating a potential upside of 12.3% from current price levels [6]